Yasunori Enomoto1, Hirotsugu Kenmotsu2, Naohiro Watanabe3, Tomohisa Baba4, Haruyasu Murakami2, Kiyotaka Yoh3, Takashi Ogura4, Toshiaki Takahashi2, Koichi Goto3, Terufumi Kato4. 1. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan Second Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan yasuyasuyasu29@yahoo.co.jp enomotoy@hama-med.ac.jp. 2. Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan. 3. Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. 4. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan.
Abstract
AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). PATIENTS AND METHODS: Twenty-five patients with non-squamous NSCLC with ILD who underwent CPB therapy between March 2007 and July 2013 were analyzed for treatment profiles. RESULTS: The median age was 67 (range=53-79) years and 96% were men. The triplet chemotherapy was repeated for a median of four cycles. The objective response rate was 72% (18/25), the median progression-free survival time was 7.2 months, and the median overall survival time was 8.5 months. The most frequent adverse event of grade 3 or more was neutropenia (72%, 18/25). Chemotherapy-induced acute exacerbation of ILD occurred in 12% of patients. CONCLUSION: CPB therapy may be an effective and feasible regimen even for patients with ILD, although clinicians should be concerned regarding neutropenia and acute exacerbation of ILD. Copyright
AIM: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD). PATIENTS AND METHODS: Twenty-five patients with non-squamous NSCLC with ILD who underwent CPB therapy between March 2007 and July 2013 were analyzed for treatment profiles. RESULTS: The median age was 67 (range=53-79) years and 96% were men. The triplet chemotherapy was repeated for a median of four cycles. The objective response rate was 72% (18/25), the median progression-free survival time was 7.2 months, and the median overall survival time was 8.5 months. The most frequent adverse event of grade 3 or more was neutropenia (72%, 18/25). Chemotherapy-induced acute exacerbation of ILD occurred in 12% of patients. CONCLUSION:CPB therapy may be an effective and feasible regimen even for patients with ILD, although clinicians should be concerned regarding neutropenia and acute exacerbation of ILD. Copyright
Authors: Stacey-Ann Whittaker Brown; Maria Padilla; Grace Mhango; Emanuela Taioli; Charles Powell; Juan Wisnivesky Journal: Ann Am Thorac Soc Date: 2019-08